Form 4 for GLUE Monte Rosa Therapeutics, Inc.
Accepted 2026-06-30 16:05:37 ET · period of report 2026-06-29 · accession 0001193125-26-290486 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-06-30 16:05 | 2026-06-29 | GLUE | Janku Filip | Chief Medical Off | M - OptEx | $7.56 | +6,000 | 66.0K | +10% | +$45.4K |
| DT | 2026-06-30 16:05 | 2026-06-29 | GLUE | Janku Filip | Chief Medical Off | S - Sale+OE | $22.95 | -6,000 | 60.0K | -9% | -$137.7K |
| DT | 2026-06-30 16:05 | 2026-06-29 | GLUE | Janku Filip | Chief Medical Off | M - OptEx | $0.00 | -6,000 | 60.0K | -9% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-06-29 | M | A | 6,000 | $7.56 | 65,992 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. |
| 2 | Common | Common Stock | 2026-06-29 | S | D | 6,000 | $22.95 | 59,992 | D | — | — | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. |
| 3 | Derivative | Stock Option (Right to Buy) | 2026-06-29 | M | D | 6,000 | $0.00 | 60,000 | D | $7.56 · — to 2032-10-03 | 6,000 Common Stock | (F1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026. (F2) The shares underlying this option are fully vested and exercisable. |